Yelena Y. Janjigian
0000-0002-5357-5858
Publication & Citation Trends
Publications
0 total
Abstract CT132: A Phase I/IIa clinical trial (TranStar101) to evaluate the safety, tolerability and pharmacokinetics of OSEMITAMAB administered as monotherapy or in combination with nivolumab or standard of care in patients with locally advanced or metastatic solid tumors
Cited by 5
Semantic Scholar
Abstract 3629: Prevalence of claudin18.2 expression in gastric/gastroesophageal junction adenocarcinoma among patients in TranStar101 and TranStar102 clinical trials
Cited by 0
Semantic Scholar
P-126 TROPION-PanTumor03, a phase 2, multicentre study of datopotamab deruxtecan (Dato-DXd) as monotherapy and in combination with anticancer agents in patients with advanced/metastatic solid tumours: Substudies in gastric and colorectal cancer OA
Cited by 3
Semantic Scholar
Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. OA
Cited by 111
Semantic Scholar
Immunotherapy and Targeted Therapy for Advanced Gastroesophageal Cancer: ASCO Guideline OA
Cited by 149
Semantic Scholar
P-244 Feasibility, safety, and biodistribution of 18F-BMS-986229 PET in patients with esophagogastric (EG) cancer OA
Cited by 3
Semantic Scholar
FOLFOX-Based Chemoradiation as Non-Operative Management for Esophageal Adenocarcinoma
Cited by 1
Semantic Scholar
Pharmacologically controlling protein-protein interactions through epichaperomes for therapeutic vulnerability in cancer OA
Cited by 18
Semantic Scholar
Research Topics
Gastric Cancer Management and Outcomes
(468)
Esophageal Cancer Research and Treatment
(348)
Lung Cancer Treatments and Mutations
(213)
Cancer Immunotherapy and Biomarkers
(159)
Cancer Genomics and Diagnostics
(92)
Affiliations
U.S. National Science Foundation
Memorial Sloan Kettering Cancer Center
The University of Texas MD Anderson Cancer Center
Bayer (United States)
Merck (Germany)